Despite the positive aspects such as FDA feedback, ongoing partnerships, and financial readiness, the increased net loss, rising expenses, and management's vague responses in the Q&A raise concerns. Additionally, the lack of immediate revenue-driving catalysts and the absence of market cap data suggest a limited immediate impact on stock price, resulting in a neutral sentiment.
Report
Attend Webcast
